NeoGenomics Q4 Earnings Call Highlights

1 month ago 13

MarketBeat

Tue, February 17, 2026 astatine 9:42 AM CST 8 min read

NeoGenomics logo

NeoGenomics reported grounds results for FY2025 with Q4 gross of $190 million (up 11% YoY) and full-year gross of $727 million (up 10%), marking its 10th consecutive 4th of affirmative adjusted EBITDA; 2026 guidance targets $793–$801 million successful gross and $55–$57 million successful adjusted EBITDA.
The institution is intentionally shifting distant from low‑value, high‑volume contracts toward higher‑value, therapy‑guided investigating to thrust AUP enlargement (management expects AUP maturation to beryllium the superior gross driver), which could compress volumes aboriginal successful 2026 arsenic the portfolio is rationalized.
Product and objective momentum centers connected NGS (Q4 NGS gross +23%, ~one‑third of objective revenue), the caller PanTracer Pro launch, and the commercialized roll‑out of MRD trial RaDaR ST, but meaningful publication from PanTracer LBx and broader RaDaR indications depends connected MolDX reimbursement timing.
Interested successful NeoGenomics, Inc.? Here are 5 stocks we similar better.

It's Not Too Late to Jump connected These Under-the-Radar Momentum Plays

NeoGenomics (NASDAQ:NEO) reported fourth-quarter and full-year 2025 results that absorption said reflected improving execution done the year, highlighted by grounds quarterly revenue, continued maturation successful its objective business, and advancement connected semipermanent initiatives successful next-generation sequencing (NGS) and minimal residual illness (MRD).

For the 4th fourth of 2025, the institution reported full gross of $190 million, up 11% twelvemonth implicit year. Clinical gross grew 16% from the anterior year, portion non-clinical gross declined by over 25%, accordant with expectations discussed connected the call.

→ These 3 Stocks Just Graduated to the MSCI World Index

Chief Financial Officer Jeff Sherman said adjusted gross nett accrued $5.8 million, oregon 7%, and adjusted EBITDA roseate 10% to $13.4 million. Sherman besides noted the 4th marked the company’s 10th consecutive 4th of affirmative earnings, with adjusted EBITDA and margins improving sequentially each 4th during 2025.

For full-year 2025, NeoGenomics reported full gross of $727 million, up 10% versus 2024. Clinical gross accrued 15% (or 13% excluding the PathLine acquisition), portion non-clinical gross declined 24% for the year. Adjusted gross nett accrued $23 million, oregon 8%, to $335 million, and adjusted EBITDA roseate 9% to $43.4 million. Cash travel from operations was positive $5 million successful 2025, and the institution reported that escaped currency travel improved by over 35% compared with 2024.